New Preferred Characteristics for Monoclonal Antibodies in Malaria Prevention
Passive immunization through monoclonal antibodies (mAbs) could potentially provide immediate protection against malaria. To guide the development of urgently needed health products, WHO has published preferred product characteristics (PPCs) for mAbs in malaria prevention. These PPCs aim to reduce morbidity and mortality in infants and children due to Plasmodium falciparum, and highlight the preferred characteristics and clinical development considerations for mAbs in this area. This is an exciting development alongside the development of new malaria vaccines and chemoprevention drugs.
Recent Posts
Boosting Africa Vaccine Manufacturing: A New Era of Local Production and Supply Security
Africa Vaccine Manufacturing stands to benefit from ongoing talks between Africa CDC and Aspen Pharmacare aimed at securing long-term vaccine supply agreements that strengthen local production capacity across the continent. The discussions focus on selecting priority antigens, scaling annual outp...
Compliance Challenges Under the New Procurement Regulations South Africa for Health Sector Suppliers
South Africa’s Draft General Public Procurement Regulations, 2026 establish a comprehensive framework that prioritises transparency, accountability and value for money in all public contracts under procurement regulations South Africa. For pharmaceutical, biotech and medtech companies bidding on ...
Preferential Procurement Regulations: Impact on Health Sector Suppliers in 2026
South Africa’s Preferential Procurement Regulations, embedded in the Draft General Public Procurement Regulations, 2026, introduce mandatory set-asides, pre-qualification tests and subcontracting thresholds that directly affect suppliers of active pharmaceutical ingredients, diagnostics and hospi...